TY - JOUR
T1 - COVID-19 in Pregnant Women With Rheumatic Disease
T2 - Data From the COVID-19 Global Rheumatology Alliance
AU - Bermas, Bonnie L.
AU - Gianfrancesco, Milena
AU - Tanner, Helen L.
AU - Seet, Andrea M.
AU - Aguiar, Mathia C.
AU - Al Adhoubi, Nasra K.
AU - Al Emadi, Samar
AU - Cunha, Bernardo M.
AU - Flood, Rachael
AU - Kusevich, Daria A.
AU - McCarthy, Eoghan M.
AU - Patel, Naomi J.
AU - Ruderman, Eric M.
AU - Sattui, Sebastian E.
AU - Sciascia, Savino
AU - Siddique, Faizah
AU - Valenzuela-Almada, Maria O.
AU - Wise, Leanna M.
AU - Worthing, Angus B.
AU - Zell, Jo Ann
AU - Bhana, Suleman
AU - Costello, Wendy
AU - Duarte-Garcia, Ali
AU - Grainger, Rebecca
AU - Gossec, Laure
AU - Hausmann, Jonathan S.
AU - Hyrich, Kimme
AU - Lawson-Tovey, Saskia
AU - Liew, Jean W.
AU - Sirotich, Emily
AU - Sparks, Jeffrey A.
AU - Sufka, Paul
AU - Wallace, Zachary S.
AU - Machado, Pedro M.
AU - Strangfeld, Anja
AU - Clowse, Megan E.B.
AU - Yazdany, Jinoos
AU - Robinson, Philip C.
N1 - Publisher Copyright:
© 2022 The Journal of Rheumatology.
PY - 2022/1/1
Y1 - 2022/1/1
N2 - Objective. To describe coronavirus disease 2019 (COVID-19) and pregnancy outcomes in patients with rheumatic disease who were pregnant at the time of infection. Methods. Since March 2020, the COVID-19 Global Rheumatology Alliance has collected cases of patients with rheumatic disease with COVID-19. We report details of pregnant women at the time of COVID-19 infection, including obstetric details separately ascertained from providers. Results. We report on 39 patients, including 22 with obstetric detail available. The mean and median age was 33 years, range 24–45 years. Rheumatic disease diagnoses included rheumatoid arthritis (n = 9), systemic lupus erythematosus (n = 9), psoriatic arthritis/other inflammatory arthritides (n = 8), and antiphospholipid syndrome (n = 6). Most had a term birth (16/22), with 3 preterm births, 1 termination, and 1 miscarriage; 1 woman had yet to deliver at the time of report. One-quarter (n = 10/39) of pregnant women were hospitalized following COVID-19 diagnosis. Two of 39 (5%) required supplemental oxygen (both hospitalized); no patients died. The majority did not receive specific medication treatment for their COVID-19 (n = 32/39, 82%), and 7 patients received some combination of antimalarials, colchicine, anti–interleukin 1β, azithromycin, glucocorticoids, and lopinavir/ritonavir. Conclusion. Women with rheumatic diseases who were pregnant at the time of COVID-19 had favorable outcomes. These data have limitations due to the small size and methodology; however, they provide cautious optimism for pregnancy outcomes for women with rheumatic disease particularly in comparison to the increased risk of poor outcomes that have been reported in other series of pregnant women with COVID-19.
AB - Objective. To describe coronavirus disease 2019 (COVID-19) and pregnancy outcomes in patients with rheumatic disease who were pregnant at the time of infection. Methods. Since March 2020, the COVID-19 Global Rheumatology Alliance has collected cases of patients with rheumatic disease with COVID-19. We report details of pregnant women at the time of COVID-19 infection, including obstetric details separately ascertained from providers. Results. We report on 39 patients, including 22 with obstetric detail available. The mean and median age was 33 years, range 24–45 years. Rheumatic disease diagnoses included rheumatoid arthritis (n = 9), systemic lupus erythematosus (n = 9), psoriatic arthritis/other inflammatory arthritides (n = 8), and antiphospholipid syndrome (n = 6). Most had a term birth (16/22), with 3 preterm births, 1 termination, and 1 miscarriage; 1 woman had yet to deliver at the time of report. One-quarter (n = 10/39) of pregnant women were hospitalized following COVID-19 diagnosis. Two of 39 (5%) required supplemental oxygen (both hospitalized); no patients died. The majority did not receive specific medication treatment for their COVID-19 (n = 32/39, 82%), and 7 patients received some combination of antimalarials, colchicine, anti–interleukin 1β, azithromycin, glucocorticoids, and lopinavir/ritonavir. Conclusion. Women with rheumatic diseases who were pregnant at the time of COVID-19 had favorable outcomes. These data have limitations due to the small size and methodology; however, they provide cautious optimism for pregnancy outcomes for women with rheumatic disease particularly in comparison to the increased risk of poor outcomes that have been reported in other series of pregnant women with COVID-19.
KW - COVID-19
KW - anti-TNF
KW - disease-modifying antirheumatic drug
KW - rheumatoid arthritis
KW - rheumatology
UR - http://www.scopus.com/inward/record.url?scp=85123225600&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85123225600&partnerID=8YFLogxK
U2 - 10.3899/jrheum.210480
DO - 10.3899/jrheum.210480
M3 - Article
C2 - 34470798
AN - SCOPUS:85123225600
SN - 0315-162X
VL - 49
SP - 110
EP - 114
JO - Journal of Rheumatology
JF - Journal of Rheumatology
IS - 1
ER -